Talimogene laherparepvec is a prescription medicine indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. It is available as injectable suspension for intralesional use. MedsAcross supplies Talimogene laherparepvec for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use: IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases.
Source: US FDA prescribing information
IMLYGIC has been genetically modified to replicate within tumors and to produce the immune stimulatory protein GM-CSF. IMLYGIC causes lysis of tumors, followed by release of tumor-derived antigens, which together with virally derived GM-CSF may promote an antitumor immune response. However, the exact mechanism of action is unknown.
Source: US FDA prescribing information
For intralesional injection only. Do not administer intravenously. Administer IMLYGIC by injection into cutaneous, subcutaneous, and/or nodal lesions. Recommended starting dose is up to a maximum of 4 mL of IMLYGIC at a concentration of 10 6 (1 million) plaque-forming units (PFU) per mL. Subsequent doses should be administered up to 4 mL of IMLYGIC at a concentration of 10 8 (100 million) PFU per mL.
Source: US FDA prescribing information
Immunocompromised Patients. Pregnant Patients Immunocompromised Patients IMLYGIC is a live, attenuated herpes simplex virus and may cause life-threatening disseminated herpetic infection in patients who are immunocompromised. Do not administer IMLYGIC to immunocompromised patients, including those with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy.
Source: US FDA prescribing information
Accidental Exposure to IMLYGIC: Accidental exposure may lead to transmission of IMLYGIC and herpetic infection. Healthcare providers and close contacts should avoid direct contact with injected lesions, dressings, or body fluids of treated patients. Accidental Exposure to IMLYGIC continued: Healthcare providers who are immunocompromised or pregnant should not prepare or administer IMLYGIC. If accidental exposure occurs, exposed individuals should clean the affected area. Herpetic Infection: Patients who develop herpetic infections should be advised to follow standard hygienic practices to prevent viral transmission. Injection Site Complications: Consider the risks and benefits before continuing IMLYGIC treatment if persistent infection or delayed healing develops.
Source: US FDA prescribing information
The most commonly reported adverse drug reactions (≥ 25%) in IMLYGIC-treated patients were fatigue, chills, pyrexia, nausea, influenza-like illness, and injection site pain. The following adverse reactions are discussed in greater detail in another section of the label: Herpetic Infection Injection Site Complications The most commonly reported adverse drug reactions (≥ 25%) in IMLYGIC-treated patients were fatigue, chills, pyrexia, nausea, influenza-like illness, and injection site pain.
Source: US FDA prescribing information
IMLYGIC is sensitive to acyclovir. Acyclovir or other antiherpetic viral agents may interfere with the effectiveness of IMLYGIC. No drug interaction studies have been conducted with IMLYGIC.
Source: US FDA prescribing information
Store and transport IMLYGIC at −90°C to −70°C (−130°F to −94°F). Store IMLYGIC in the carton until use.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Talimogene laherparepvec, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Imlygic 1000000 PFU/mL injectable suspensionIntralesional Cold chain | Amgen | US FDA | Available on request |
| Imlygic 100000000 PFU/mL injectable suspensionIntralesional Cold chain | Amgen | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Talimogene laherparepvec in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Talimogene laherparepvec and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Talimogene laherparepvec, including Imlygic.
Yes. Talimogene laherparepvec has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Talimogene laherparepvec must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Talimogene laherparepvec is classified under ATC code L01XL02 (Talimogene laherparepvec).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.